Trial Profile
Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms PAINTER
- 28 Oct 2022 Results assessing the tolerability of eribulin in metastatic breast cancer patients, published in the Breast Cancer Research.
- 03 Mar 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium